Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

NCT07215273 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Invasive Mould Infection

Interventions

DRUG: EL219
DRUG: Active Comparator- IV Antifungal (LAmB or voriconazole)

Sponsor

Elion Therapeutics, Inc.